Pemvidutide

Also known as: ALT-801

Emerging evidence
ClassDual GLP-1/glucagon receptor agonist
Research statusPhase 2 clinical trials
CategoryGLP-1 / incretin
Independent tests3
Studies indexed3
Companies tested 3

Overview

A balanced GLP-1/glucagon co-agonist designed to drive weight loss while preserving lean mass, with MASH as a lead indication.

Pemvidutide is classified as a dual glp-1/glucagon receptor agonist. Its current development status is: phase 2 clinical trials. Most of the evidence is preclinical. Human data is early, small, or absent for the uses commonly discussed.

The Peptide Institute tracks Pemvidutide because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.

Independent Testing

Independently tested companies that sell Pemvidutide

Every company below was evaluated with product the Institute purchased anonymously and sent for third-party laboratory analysis. Ranked by Index Score™.

Companies
3
Samples
3
Updated
Mar 5, 2026
  1. 1 Apex Peptides Exceptional Institute
    Top Rated     Pemvidutide

    94.5% average purity across 1 sample

    Purity & Testing 99 Transparency 90 Samples 1 91 View company
  2. 2 Quantum Peptide Group Excellent

    97.7% average purity across 1 sample

    Purity & Testing 98 Transparency 85 Samples 1 89 View company
  3. 3 Northwind Telehealth Excellent

    96.5% average purity across 1 sample

    Purity & Testing 81 Transparency 90 Samples 1 84 View company
Compare all tested Pemvidutide companies

Research & Studies

Studies library

  • A systematic review of Pemvidutide clinical evidence

    Peptides · Systematic review · Jul 13, 2025

    Characterises Pemvidutide activity in a controlled setting. Endpoints are surrogate measures rather than clinical outcomes.

  • Comparative effects of Pemvidutide on metabolic endpoints

    The Lancet Diabetes & Endocrinology · Open-label extension study · Apr 12, 2020

    Reports findings relevant to the primary claims made for Pemvidutide; sample size limits how far the result generalises.

  • Long-term outcomes with Pemvidutide: an open-label extension

    Journal of Controlled Release · Pharmacokinetic study (Phase 1) · Sep 16, 2019

    One of the more methodologically careful entries in the Pemvidutide literature.

Independent Testing

Testing database

Laboratory verification of Pemvidutide products across the companies we index.

Pemvidutide Northwind Telehealth
Purity 96.5% Verified
Pemvidutide Apex Peptides
Purity 94.5% Verified
Pemvidutide Quantum Peptide Group
Purity 97.7% Verified

Community Discussions

Forum

The Peptide Institute Weekly

Research. Testing. Regulation. No hype.

One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.

  • New research, summarized in plain English
  • Independent lab results as they publish
  • Score and ranking movements